DJIA 15,234.89 -59.61 -0.39%
NASDAQ 3,440.84 -18.58 -0.54%
S&P 500 1,640.95 -9.56 -0.58%

VIVUS, Inc.

NASDAQ: VVUS

15.03 0.53 (3.66%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $15.08 4.00%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $14.42
Previous Close $14.50
Daily Range $14.33 - $14.90
52-Week Range $9.86 - $31.21
Market Cap $1.5B
P/E Ratio -8.29
Dividend (Yield) $0.00 (0.0%)
Volume 889,317
Average Daily Volume 2,716,425
Current FY EPS -$1.91

Sector

Healthcare

Industry

Drugs

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website: http://www.vivus.com/

News & Commentary

First Manhattan Adds Alex Denner to Vivus Board Slate

Vivus Heats Up, Shorts Discouraged On Possible Bidding War

Arena - Good Sales, Bad Sales, Long And Short

Bullish Two Hundred Day Moving Average Cross - VVUS

UPDATE: Dissident Holder First Manhattan Adds Three to Vivus Board Slate

Dissident Holder First Manhattan Adds 3 to Vivus Board Slate

Will Arena's Belviq Be The Next Anti-Obesity Drug To Make The Cover Of Time Magazine?

3 Pipeline Obesity Treatments You Should Watch

In the past year, two approved obesity drugs put the massive obesity market within reach of investors. Here are three treatments under development that could have even bigger consequences.

Arena Pharmaceuticals - Out To Launch Or Out To Lunch?

The Surprising Link Between ADHD and Obesity

This disorder in childhood could put your adult health at risk.

See More VVUS News...

VVUS's Top Competitors

VVUS $15.03 (3.66%)
Current stock: VVUS
JNJ $86.70 (-0.58%)
Current stock: JNJ
NVS $74.06 (0.33%)
Current stock: NVS
RHHBY $65.65 (0.14%)
Current stock: RHHBY